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Introduction
Panic disorder is characterized by occasional panic attacks, anticipatory anxiety and frequent 
development of agoraphobia. The lifetime prevalence of panic disorder is 1 to 4 percent, with 
6-month prevalence approximately 0.5 to 1.0 percent, and 3 to 5.6 percent for panic attacks.
1 
Women are two to three times more likely to be affected than men.
2 Patients with panic disorder 
often have comorbid conditions with other anxiety disorders and mood disorders, personality 
disorders and substance-related disorders. 
Abnormal brain neurotransmitter regulation is implicated in the pathophysiology of panic 
disorder. The major neurotransmitter systems such as norepinephrine, serotonin, γ-aminobutryic 
acid (GABA) are involved in panic disorder. Especially, serotonergic dysfunction is quite obvi-
ous in panic disorder.
3-7
Two opposing hypotheses could explain the relationship between panic symptoms and se-
rotonergic dysfunction
8: 5-HT excess or overactivity and 5-HT deficit or underactivity. 5-HT 
excess hypothesis suggests patients with panic disorder either have an increased level of 5-HT 
release or hypersensitivity in postsynaptic 5-HT receptors.
9-11 On the other side, 5-HT deficit 
ObjectiveaaSerotonergic dysfunction is quite evident in panic disorder. We investigated wheth-
er the C(-1019)G polymorphism of 5-HT1A receptor gene may play a role in the pathogenesis 
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MethodsaaThe 5-HT1A receptor genotype for the single nucleotide polymorphism (SNP) 
C(-1019)G was analyzed in 94 patients and 111 healthy controls. The severity of the patients’ 
symptoms was examined using the Spielberger State-Trait Anxiety Inventory (STAI), Panic 
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hypothesis implies 5-HT has a restraining effect on panic be-
havior and 5-HT deficit may facilitate panic symptoms.
12 Vari-
ous clinical studies have proved that postsynaptic serotonin hy-
persensitivity could cause increased rates of anxiety and panic 
attacks.
11 Coplan showed that selective serotonin reuptake inhibi-
tors (SSRIs) might exacerbate anxiety symptoms during the in-
itial treatment due to possible oversensitivity of postsynaptic 
5-HT receptors.
4 However, findings of numerous studies about 
the anti-panic effect of 5-HT supported the 5-HT deficit hypo-
thesis.
13 Moreover, it was reported panic disorder patients gain-
ed relief after administration of 5-HT precursor, 5-hydroxytry-
ptophan.
One of the most abundant subtypes of 5-HT receptor genes 
expressed in the mammalian brain is the serotonin 1A (5-
HT1A) receptor. 5-HT1A receptor is known to be the major au-
toreceptor of serotonergic raphe neurons.
14 Neumeister et al.
15 
reported 5-HT1A receptor binding is reduced in anterior cin-
gulate cortex, post cingulate cortex and midbrain raphe only in 
panic disorder patients by analyzing positron emission tomog-
raphy (PET) study. Nash et al.
16 also reported reduction in post-
synaptic 5-HT1A receptor binding in amygdala, temporal cor-
tex and orbitofrontal cortex in patients with untreated panic 
disorder. Therefore, 5-HT1A receptor regarded as vulnerable 
source in panic disorder patients. 
Several single nucleotide polymorphisms have been de-
scribed for 5-HT1A receptor gene.
16-25 Especially, Wu and Co-
mings
26 reported a C(-1019)G polymorphism in the promoter 
region of the 5-HT1A receptor gene. This locus is identified as 
C(-1019)G polymorphism because of the presence of an extra 
base pair in the human genome sequence of the 5-HT1A re-
ceptor gene. The subsequent study showed that 5-HT1A C(-
1019)G polymorphism is located in a transcriptional regulato-
ry region and the sequence is within a 26-bp palindrome.
27 G 
allele and/or G/G of 5-HT1A C(-1019)G polymorphism geno-
type was found to be associated with major depression and sui-
cide.
14 
Up to date, many studies have focused on the serotonergic 
system to determine the vulnerable gene of panic disor-
der.
23-25, 27-36 However, association studies between the C(-1019)
G polymorphism and panic disorder have shown inconclusive 
findings.
37 Huang et al.
21 reported no association of panic dis-
order with the G allele. Rothe et al.
25 showed no association be-
tween C(-1019)G polymorphism and all patients with panic 
disorder. On the other hand, in a subsequent study, Rothe et 
al.
25 showed significant association between the G allele and 
panic disorder with agoraphobia. Maron et al.
32 revealed an as-
sociation between the C allele and panic disorder. The recent 
study showed G allele associated with significantly reduced 
anxiety-related amygdala reactivity.
38 
So, we investigated if C(-1019)G polymorphism of 5-HT1A 
receptor could be associated with panic disorder in a Korean 
population. To our knowledge, this is the first study to explore 
the relation between 5-HT1A receptor gene and panic disor-
der in a Korean population.   
Methods
 
Subjects 
The study subjects recruited 110 panic patients. The diagno-
sis of panic disorder according to DSM-IV criteria was verified 
using Structured Clinical Interview for DSM-IV (SCID).
39 The 
interviews and diagnoses were independently made by a psy-
chiatrist without knowledge of the genotypes of subjects. Pan-
ic disorder patients who had comorbidity with mood disorders 
or other psychiatric disorders were excluded. Four patients with 
comorbid major depressive disorder were excluded. The pa-
tients who had a family history of psychiatric disorders were 
excluded except for anxiety disorders. Two patients who had a 
family history of schizophrenia and two patients had a family 
history of major depressive disorder. Also, the patients who 
had medical diseases were also excluded. Six patients with ar-
rhythmia and one with asthma and another with thyroid can-
cer were excluded. Finally, this study included 94 patients with 
panic disorder. Concurrent agoraphobia was present in 70 
(74.5%) of the patients. 
We assessed the severity of the individual’s symptoms us-
ing the Spielberger State-Trait Anxiety Inventory (STAI), Pan-
ic Disorder Severity Scale (PDSS), Anxiety sensitivity index 
(ASI), Acute Panic Inventory (API) and Hamilton’s Rating Sca-
le for Anxiety (HAM-A).
The healthy volunteers were recruited by advertisements 
in newspapers. They were interviewed with SCID and were qu-
estioned about their personal or family history of psychiatric 
disorders. Healthy controls that had a personal or family his-
tory of psychiatric disorders among first-degree relatives were 
excluded in this study. Some of them were excluded because 
of their comorbid medical conditions. Finally, 111 healthy con-
trols were included in this study.
The mean age of panic disorder patients was 40.1±9.5 years, 
and the mean age of control groups was 38.3±7.3 years. There 
was no significant difference of the mean age between both 
groups (t=-1.533, p=0.127). No significant difference was found 
in gender distribution between the panic disorder patients (male : 
female=52 : 42) and healthy controls (male : female=52 : 59) 
(χ2=1.462, p=0.227). Age of onset of panic disorder was 37.2 
±9.5 years, and duration of panic disorder was 34.8±46.3 mon-
ths in patients with panic disorder.
DNA analysis 
Genomic DNA was extracted from blood leukocytes by us-
ing a commercial DNA extract kit, Wizard Genomic DNA pu-
rification kit (Promega, USA). Polymerase chain reaction 
(PCR) was performed with the forward primer 5’-TGG AAG 
AAG ACC GAG TGT GTC TAC-3’ and the reverse primer WS Choi et al. 
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5’-TTC TCC CTG AGG GAG TAA GGC TGG-3’. The am-
plification mixture contained 1 uL of 100 ng/uL DNA, 2.5 uL 
of 10x Ex Taq buffer, 2 uL of 2.5 mM Ex dNTP mixture, 1 uL 
primer, 18.375 uL distilled water, and 0.125 uL Taq polymer-
lase (TaKaRa, Japan). Samples were amplified using a Thermo-
cycler (GeneAmp PCR system 2700, Applied Biosystems, 
Foster City, CA, USA) for 36 cycles. After an initial 5 min at 
95℃, each cycle consisted of 45 sec at 95℃, 45 sec at 56℃, 
and 45 sec at 72℃. After a final 10 min at 72℃, the reaction 
was terminated at 4℃. The amplified DNA was digested with 
the restriction enzyme Hpy CH4IV (New England Biolabs), 
which cuts at the -1019G site, and the product was electro-
phoresed in 3% agarose gels and stained with ethidium bro-
mide. Homozygous genotypes were identified by the pres-
ence of a single 182 bp band (C/C), or bands of 158 and 24 
bp (G/G). The heterozygous genotype had three bands: 182, 
158, and 24 bp (C/G)(Figure 1). 
Statistical analysis
The presence of Hardy-Weinberg equilibrium was tested by 
a χ2 test for goodness of fit. Differences of clinical variables 
were examined with t-test. Allele and genotype frequencies in 
patients with panic disorder and healthy controls were evalu-
ated using the χ2 test. Effect of genotype on symptom severity 
was examined with t-test, analysis of variance (ANOVA), Ma-
nn-Whitney test and Kruskal-Wallis test by comparing the 
mean scores of each genotype. These analyses were performed 
using Statistical Package for the Social Sciences (SPSS)(ver-
sion 12.0; SPSS Inc., Chicago, IL, USA). The level of statisti-
cal significance was set at p<0.05. Moreover, the power anal-
ysis was performed with using of G-Power 3.1.0 computer 
software.
40
Results
The genotype distributions in the panic disorder patients 
(p=0.99) and in the controls (p=0.98) were in agreement with 
the Hardy-Weinberg equilibrium. 
No significant association between the C(-1019)G polymor-
phism and panic disorder was detected in either the allele fre-
quency or genotype distribution (Table 1). There was no signif-
icant association between the C(-1019)G polymorphism and 
panic disorder with agoraphobia (Table 1). The C(-1019)G poly-
morphism had no significant differences between patients with 
panic disorder and healthy controls after correction of statisti-
cal differences of the gender and agoraphobia.
There were no significant differences of scores in panic symp-
tom severity scales between C/C, C/G, and G/G genotype in 
all patients with panic disorder (Table 2) or between those in 
patients with agoraphobia (Table 3). However, patients without 
Table 1. Genotype and allele frequencies of the 5-HT1A C(-1019)G promotor polymorphism in panic disorder patients and control groups
Sample 
Genotypes
χ2  p
Alleles
χ2 p
C/C C/G G/G C  G
Panic disorder
Male (N=52) 4 23 25 0.859  0.651 31 073 0.604  0.437
Female (N=42) 3 20 19 0.485  0.785 26 058 0.108  0.743
Total (N=94)  7 43 44 0.617  0.734 57 131 0.541  0.462
Normal controls 
Male (N=52) 2 22 28 26 078
Female (N=59) 5 24 30   34 084
Total (N=111) 7 46 58   60 162
Panic disorder with agoraphobia
Male (N=40) 4 17 19 2.590  0.629 25 055 0.882  0.348
Female (N=30) 1 13 16 4.270  0.371 15 045 0.290  0.590
Total (N=70) 5 30 35 1.742  0.783 40 100 0.102  0.749
182 bp
158 bp
24 bp
Figure 1. Agarose gel eletrophoretogram of HTR1A C(-1019)G 
PCR product after digestion with Hpy CH4IV. Lane M: molecular 
weigh marker; lane I: C/C (182 bp), lane II: C/G (182, 158, 24 bp), 
lane III: G/G(158, 24 bp), PCR: polymerase chain reaction.144  Psychiatry Investig 2010;7:141-146
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agoraphobia had significant difference of PDSS score between 
C/C, C/G, and G/G genotype or between C and G allele (Table 
4). The PDSS scores were significantly higher in subjects with 
the G/G genotype for 5-HT1A C(-1019)G than in those with 
the C/C genotype (p=0.036). Also, patients with G allele had 
significantly higher PDSS score than those with C allele (p= 
0.025).
This study had a power of approximately 0.23 to detect a 
small effect, and 0.97 to detect a medium effect, and 0.99 to de-
tect a large effect in the genotype frequencies (n=205 for to-
tal sample). When given a power of 0.95, we were able to de-
tect an effect size of 0.28 for detecting a significant difference 
in genotype distributions of total panic disorder. In the allele 
distributions (n=410 for total sample), the study power were 
0.53 to detect a small effect, 0.99 to detect a medium and a large 
effect, respectively. In this power analysis, effect size conven-
tions were determined according to the method of Buchner et 
al.
40 as follows: small effect size=0.10, medium effect size= 
0.30, large effect size=0.50 (alpha=0.05).
Discussion
In this study, We did not find a genetic association between 
the C(-1019)G polymorphism of the 5-HT1A receptor gene 
and panic disorder in our samples. Furthermore, no association 
was observed between the C(-1019)G polymorphism of the 
5-HT1A receptor gene and panic disorder with agoraphobia. 
Our results are consistent with previous studies. Huang et al. 
21 
reported no association of panic disorder with the G allele.
Rothe et al.
25 showed no association between C(-1019)G poly-
morphism and all patients with panic disorder. However,   
Rothe et al.
25 subsequently reported the association between 
C(-1019)G polymorphism and panic disorder with agorapho-
bia and indicated a significant excess of the G allele in patients 
Table 2. Comparison of symptom severity in patients with panic disorder according to 5-HT1A C(-1019)G genotype
  Genotypes
F p
Alleles
t p
C/C (N=7) C/G (N=43) G/G (N=44) C (N=57)  G (N=131)
STAI 94.29±26.12 91.30±22.98 96.30±24.16 0.481 0.619 92.04±23.32 94.61±23.71 -0.700 0.485
API 19.00±15.98 18.93±8.840 19.43±11.37 0.025 0.975 18.95±10.65 19.27±10.53 -0.191 0.849
ASI 34.71±20.12 33.12±12.53 34.36±15.90 0.091 0.913 33.51±14.32 33.95±14.77 -0.192 0.848
PDSS 10.43±9.200 10.98±8.490 12.20±8.350 0.290 0.749 10.84±8.500 11.80±8.350 -0.720 0.186
Ham-A 15.29±8.580 14.12±9.510 14.48±7.630 0.062  0.940 14.40±9.150 14.36±8.230 -0.033 0.974
Mean±SD. STAI: Spielberger State-Trait Anxiety Inventory, API: Acute Panic Inventory, ASI: Anxiety Sensitivity Index, PDSS: Panic 
Disorder Severity Scale, HAM-A: Hamilton’s Rating Scale for Anxiety
Table 3. Comparison of symptom severity in panic disorder with agoraphobia patients according to 5-HT1A C(-1019)G genotype
  Genotypes
F p
Alleles
t p
C/C (N=7) C/G (N=43) G/G (N=44) C (N=40)  G (N=100)
STAI 100.80±24.41 96.67±19.40 98.66±26.24 0.098 0.907 97.70±20.14 98.06±24.17  -0.083 0.934
API 023.20±16.66 21.57±7.910 19.63±11.84 0.409 0.666 21.98±10.20 20.21±10.74 0.891 0.375
ASI 040.00±21.68 37.23±12.17 35.80±17.05 0.191 0.827 37.92±14.42 36.23±15.60 0.593 0.554
PDSS 12.80±9.96 12.83±8.770 11.86±8.96 0.103 0.902 12.83±8.800 12.15±8.830 0.409 0.683
Ham-A 18.00±7.07 15.40±10.07 14.17±8.19 0.456  0.636 16.05±9.320 14.54±8.720 0.907 0.366
Mean±SD. STAI: Spielberger State-Trait Anxiety Inventory, API: Acute Panic Inventory, ASI: Anxiety Sensitivity Index, PDSS: Panic 
Disorder Severity Scale, HAM-A: Hamilton’s Rating Scale for Anxiety
Table 4. Comparison of symptom severity in panic disorder without agoraphobia patients according to 5-HT1A C(-1019)G genotype
 
 
Genotypes
χ
2† p
Alleles
χ
2‡ p
C/C (N=2) C/G (N=13) G/G (N=9) C (N=17)  G (N=31)
STAI 78.00±31.11 78.92±26.45 87.11±9.55 1.742 0.418 78.71±25.41 83.68±18.58 -0.929 0.353
API 08.50±10.61 12.85±8.060 18.67±9.91 2.384 0.304 11.82±8.150 16.23±9.320 -1.405 0.160
ASI 21.50±7.780 23.62±7.150 28.78±8.87 2.183 0.336 23.12±6.840 26.61±8.310 -1.319 0.187
PDSS 4.50±3.54 6.69±6.14 13.56±5.53 6.622 0.036 06.18±5.550 10.68±6.580 -2.234   0.025*
Ham-A 08.50±10.61 11.15±7.590 15.67±5.12 3.550 0.169 16.05±9.320 13.77±6.500 -1.648 0.099
Mean±SD. *p<0.05, †Kruskal Wallis test, ‡Mann-Whitney test. STAI: Spielberger State-Trait Anxiety Inventory, API: Acute Panic In-
ventory, ASI: Anxiety Sensitivity Index, PDSS: Panic Disorder Severity Scale, HAM-A: Hamilton’s Rating Scale for AnxietyWS Choi et al. 
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with panic disorder with agoraphobia. Nevertheless, that as-
sociation was regarded as a false positive because the agora-
phobia subgroup was made from a consequence of popula-
tion stratification or multiple testing could not be excluded.
25
On the other hand, Maron et al.
8 reported an association be-
tween the C allele and panic disorder. However, this study re-
garded panic disorder as comorbidity to affective disorders 
and did not excluded subjects with comorbid affective disorder. 
Therefore, this study did not reveal an association between C 
allele and panic disorder in the strict sense.
Our finding of the negative association between C(-1019)G 
polymorphism and panic disorder corresponded to those from 
Inada’s study.
29 In Inada’s study, other locus of 5-HT 1A recep-
tor gene, 294G/A polymorphism, had been examined and 
there were negative associations in Japanese population.
29 
Therefore, these findings suggest that there is no association 
between the 5-HT1A receptor gene polymorphism and panic 
disorder in non-Caucasian people. 
In this study, we found a significant difference of symptom 
severity between C/C, C/G, and G/G genotype or between C 
and G allele in our panic disorder patients without agorapho-
bia. PDSS showed significant higher score in subjects with G 
allele in panic disorder without agoraphobia. Yoon et al.
36 re-
ported the association between the severity of panic symptom 
and the 5-HT 2A receptor 102T/C and 1438A/G gene. These 
findings suggest that gene related serotonin system of panic 
disorder could be explained by vulnerability or severity of pan-
ic disorder. One could not yet find exactly associated candidate 
loci of serotonin related gene because the actual susceptibility 
locus is within very small area.
38
Compared to previous Caucasian studies,
21,25,41-44 our results 
showed that the frequency of the C allele portion was much 
lower than that of the G allele portion in both panic disorder 
groups and normal control groups. Such allele distribution 
might be different from ethnic variability.
There were some limitations in this study. First, the sample 
size in our study was not sufficient to analyze the association 
for the subgroups of panic disorder. It is increasingly clear that 
very large samples are needed to detect robust associations 
given the modest effect sizes of individual susceptibility loci. 
As a result, it was likely that our studies was underpowered, 
raising the risk of false negatives as well. Although we showed 
a significant association between panic symptom severity and 
5-HT1A receptor gene C(-1019)G polymorphism in patients 
without agoraphobia, the difference is modest and cannot sur-
vive correction for multiple comparisons. Therefore, studies of 
a larger sample of panic disorder are needed to clarify the role 
of the C(-1019)G polymorphism of the 5-HT1A receptor gene 
as a risk factor for panic disorder. Second, we examined only 
one locus of the 5-HT1A receptor gene polymorphism. To get 
clear data about 5-HT1A receptor gene polymorphism and 
panic disorder, we should do examined multiple loci related 
gene in greater sample size of panic-disorder patients in the fu-
ture. Third, all the patients were evaluated in baseline. Becau-
se the patients were under medication, there is room for con-
founding factor in estimating severity evaluation and needs to 
be adjusted by medication condition.
In conclusion, we found no association between 5-HT1A re-
ceptor gene polymorphism and panic disorder in Korean pop-
ulation. The C(-1019)G polymorphism is possibly a weak can-
didate that will contribute in establishing the relationship 
between 5-HT1A receptor gene and panic disorder. Further 
studies need to evaluate different SNPs in different ethnic gr-
oups of panic-disorder patients to clarify the role of the seroto-
nergic receptor gene variant as a risk factor of panic disorder.
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